Insilico Medicine has partnered with Boehringer Ingelheim to leverage artificial intelligence (AI) technology to identify potential therapeutic targets.

Under the collaboration, Insilico’s generative machine learning technology and Pandomics Discovery Platform will be used to discover drug targets across various disease areas.

Boehringer Ingelheim Greater China External Innovation Hub head Dr Weiyi Zhang said: “We believe that Insilico’s exclusive Pandomics platform will provide huge boost to our ability to explore and identify drug targets.

“We look forward to using AI to significantly improve the drug discovery process and contribute to human health.”

Founded in 2014, Insilico utilises generative models, reinforcement learning and other machine learning approaches to generate molecular structures, synthetic biological data, identify targets and predict clinical trial outcomes.

The company created a drug discovery engine that analyses numerous samples and data types to identify disease signatures.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It can also detect the most promising targets for molecules that exist or can be produced de novo with the required parameters.

To date, Insilico raised more than $52m, including $37m last September.

Commenting on the alliance with Boehringer, Insilico Medicine founder and CEO Alex Zhavoronkov said: “Insilico Medicine is very impressed with the Research Beyond Borders group at Boehringer Ingelheim capabilities in the search of potential drug targets.

“In this collaboration, Insilico will provide additional AI capabilities to discover novel targets for a variety of diseases to benefit the patients worldwide. We are very happy to partner with such an advanced group.”

In December, Boehringer partnered with UK-based drug technology firm Healx to use AI for identifying approaches to treat rare neurological disorders.

The partners agreed to advance Boehringer’s drug discovery programme using Healx’s AI technologies and expertise in rare diseases and pharmacology.